Navigation Links
Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
Date:4/7/2008

Delivery Systems and Specific Molecular Structures Needed for siRNA

Therapeutic Success

LONDON, April 7, 2008 /PRNewswire/ -- Silence Therapeutics plc (AIM:SLN) Europe's leading RNAi-focused biotechnology company, today comments on two recent journal articles: Nature(1) "Sequence-and target-independent angiogenesis suppression by siRNA via TLR3" Mark E. Kleinman, et. al., and Molecules and Cells(2) "Immune Activation by siRNA/Liposome Complexes in Mice is Sequence-Independent: Lack of a Role for Toll-like Receptor 3," Kim et. al. In these two publications, researchers questioned current thinking on the mode of action of siRNA therapeutics suggesting that they work by mechanisms other than via specific gene silencing.

Data published in the Nature article (Kleinman et. al.) have been interpreted in recent days in the lay press as a "Setback for Some RNA-Based Drugs" (New York Times(5)). Silence Therapeutics views the cited Nature paper, and another recent paper in Molecules and Cells(2) as highlighting the need for a functional delivery system to ensure the therapeutic siRNA is able to enter cells and achieve gene silencing.

Both studies further reinforce the importance of chemically modifying siRNA to create molecular structures which do not cause unwanted immune stimulation such as cytokine release and interferon response.

The two new studies support the long-standing development approach of Silence Therapeutics, which has focused its research on developing both a potent RNAi-mediating delivery system (AtuPLEX) and chemically-modified siRNA (AtuRNAi) molecules.

Jeff Vick, CEO of Silence Therapeutics, said, "More than eight years ago, Silence Therapeutics recognized the need for, and pioneered the development of, a functional systemic RNAi delivery system that combines proprietary chemical modification and lipid technologies to achieve efficient intracellular uptake without triggering an immune system response. This approach has allowed us to successfully demonstrate the inhibition of solid tumor growth and the spread of metastases. Silence continues to develop additional delivery technologies to broaden the clinical applications of our promising new class of siRNA therapeutics."

Silence Therapeutics has previously reported in 2006, in two peer reviewed publications in Gene Therapy(3,4), the functional in vivo delivery of different AtuRNAi-lipoplexes (chemically modified siRNA molecules formulated in a proprietary lipid complex). In particular, Silence Therapeutics' AtuPLEX formulation was shown to both avoid immune responses (published data demonstrates lack of activation of interferon-alpha and IL-12) and induce RNAi-mediated gene silencing as demonstrated by the selective inhibition of endogenous target-specific gene expression in vivo. Furthermore, independent publications by Judge(6) and Kim(2) also demonstrate that the chemical modification modality utilized in AtuRNAi obviates an immune response.

These Gene Therapy papers also show that the target-specific knockdown (gene silencing) resulted in the modulation of a specific biochemical signaling pathway containing the target, thus demonstrating the potential therapeutic benefits in certain oncology indications.

The multi-faceted approach that Silence Therapeutics has taken to realize the enormous potential of siRNA therapeutics was substantiated by Dr. Alan Sachs, Vice President for RNA Therapeutics at Merck Research Laboratories, a unit of Merck, who was quoted in the New York Times,(5) saying that "future versions of RNA drugs could be encapsulated in fat globules and chemically modified. That would help the drugs enter cells and keep them from setting off the immune system."

Jeff Vick further commented, "That future is now. This is the exact approach pioneered by Silence Therapeutics. Our current pipeline is based on combining our state-of-the-art AtuRNAi molecules and AtuPLEX drug delivery system. We have strong evidence that the siRNA therapeutics we are developing do enter mammalian cells, are appropriately localized intracellularly, and do act by selectively silencing the specifically targeted gene. We believe by continuing to build on this unique expertise we will achieve our goal of becoming a global leader in the RNAi space."

Footnotes:

Kleinman et. al., Nature(1), "Sequence-and target-independent angiogenesis suppression by siRNA via TLR3 | doi: 10.1038/nature06765; Received published online 26 March 2008."

Kim et. al., Molecules and Cells(2), Vol. 24, 247, 2007: "Immune Activation by siRNA/Liposome Complexes in Mice Is Sequence-independent: Lack of a Role for Toll-like Receptor 3 Signalling."

Santel et. al., Gene Therapy(3) 2006 Sep;13(18):1360-70. "RNA interference in the mouse vascular endothelium by systemic administration of siRNA- lipoplexes for cancer therapy."

Santel et. al., Gene Therapy(4) 2006 Aug;13(16):1222-34. "A novel siRNA- lipoplex technology for RNA interference in the mouse vascular endothelium."

New York Times(5), April 2, 2008. "Study is a Setback for Some RNA-Based Drugs."

Adam D. Judge, Gurneet Bola, Amy C.H. Lee, Ian MacLachlan, Molecular Therapy(6) Vol. 13, No. 3, March 2006: "Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo."

Notes to Editors:

About Silence Therapeutics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (AIM:SLN) is a leading RNAi company. RNA interference (RNAi) can selectively 'silence' genes linked to the onset of disease.

Silence Therapeutics has developed novel, proprietary short interfering RNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules as they show increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This enables the delivery of siRNA molecules to targeted diseased tissues and cells, whilst increasing their bioavailability and intracellular uptake.

In July 2007, Silence Therapeutics formed a research and development collaboration with AstraZeneca to develop AtuRNAi against five specific targets including those in respiratory indications. The Company's AtuRNAi technology also has been sublicensed to Pfizer through Quark's license to Pfizer of the compound RTP-801i-14 for the treatment of Age-related Macular Degeneration (AMD) and a number of other indications. This compound entered the clinic in early 2007. Silence Therapeutics also has licensed to Quark rights to the AtuRNAi structure for its proprietary compound AKIi-5. This compound is in a Phase I human clinical study for treatment of acute kidney injury. In addition, Silence Therapeutics expects to begin the clinical development of its own proprietary AtuRNAi therapeutic molecules for systemic cancer indications in 2008.

Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AIM.


'/>"/>
SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
4. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
5. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
6. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
7. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
8. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
9. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
10. Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... DUBLIN , Feb. 8, 2016 /PRNewswire/ ... announced the addition of the "Label-Free ... Global Forecasts to 2020" report to ... has announced the addition of the ... - Global Forecasts to 2020" report ...
(Date:2/8/2016)... , Feb. 8, 2016  Dynatronics Corporation (NASDAQ: ... advanced-technology medical devices and rehabilitation equipment for the ... the Denver Broncos, football team for winning the ... Jr. , Chairman and Chief Executive Officer.  "The ... we look forward to enhancing their athletic achievements ...
(Date:2/8/2016)... 8, 2016 --> ... by Allied Market Research titled, "World Synthetic ... 2014-2020", estimates the world synthetic biology market to ... sequencing technology segment would continue to lead the ... segment, collectively, held around half of the market ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub some dirt on ... A~, author of “Calcium Bentonite Clay” the health benefits of integrating clay into a ... the body. , A former motivational speaker, Perry A~ has since dedicated her life ...
(Date:2/8/2016)... Gaithersburg, MD (PRWEB) , ... February 08, 2016 ... ... (AHCC) is excited to share this important news! AHCC and the Home Health ... (AHA) Coding Clinic, CMS' designee for official ICD coding guidance and clarifications, to ...
(Date:2/8/2016)... ... , ... According to research by the National Association of ... be certified or obtain continuing education. To increase patient awareness of the lack ... campaign to inform dentists and patients about the possible lack of skills and ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/5/2016)... Florida (PRWEB) , ... February 05, 2016 , ... Steven ... event he has completed every year since it started in 2003. This year, he ... the attention of fellow runners and NBA team the Miami Heat. , This Sunday, ...
Breaking Medicine News(10 mins):